Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kohjin Bio CoTSE:177A +0.48%17 Debt-to-EBITDA is 1.56 as of Mar. 2026, which is 20% below its 10-year median of 1.96. GuruFocus rates TSE:177A with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 304 Biotechnology companies, Kohjin Bio Co ranks worse than 66.12% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Kohjin Bio Co's Debt-to-EBITDA or its related term are showing as below:
TSE:177A'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.45 Med: 1.96 Max: 2.99
Current: 2.99
During the past 5 years, the highest Debt-to-EBITDA Ratio of Kohjin Bio Co was 2.99. The lowest was 1.45. And the median was 1.96.
TSE:177A's Debt-to-EBITDA is ranked worse than 66.12% of 304
companies
in the Biotechnology industry
Industry Median: 1.215
vs TSE:177A: 2.99
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Kohjin Bio Co Debt-to-EBITDA Related Terms
Kohjin Bio Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Kohjin Bio Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:177A vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Kohjin Bio Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kohjin Bio Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kohjin Bio Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kohjin Bio Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Kohjin Bio Co (TSE:177A) has a Debt-to-EBITDA of 1.56 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kohjin Bio Co. This is 20% below median its historical median of 1.96. Over the past decade, Kohjin Bio Co's Debt-to-EBITDA has ranged from 1.45 to 2.99. According to the industry distribution chart, Kohjin Bio Co ranks #201 out of 304 companies in the Biotechnology industry, placing it in the top 66.1%.
Is Kohjin Bio Co's Debt-to-EBITDA too high?
Kohjin Bio Co's current Debt-to-EBITDA of 1.56 is 20% below median its 10-year median of 1.96. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 2.99. The Biotechnology industry median Debt-to-EBITDA is 1.22. Kohjin Bio Co's value of 1.56 is 28.4% above this industry median. Based on the distribution chart, Kohjin Bio Co ranks #201 out of 304 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kohjin Bio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Kohjin Bio Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kohjin Bio Co ranks #201 out of 304 companies for Debt-to-EBITDA. This places Kohjin Bio Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.22. Kohjin Bio Co's value of 1.56 is 28.4% above this benchmark. Historically, Kohjin Bio Co's own Debt-to-EBITDA has ranged from 1.45 to 2.99 over the past decade. While the company's 10-year median is 1.96 vs. the industry median of 1.22, Kohjin Bio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.22, based on 304 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kohjin Bio Co's current Debt-to-EBITDA of 1.56 is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kohjin Bio Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kohjin Bio Co's current Debt-to-EBITDA is 1.56, which is 20% below median its own 10-year median of 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kohjin Bio Co stock overvalued right now?
Kohjin Bio Co (TSE:177A) has a current Debt-to-EBITDA of 1.56. The current Debt-to-EBITDA is 1.56, which is 20% below median its 10-year median of 1.96 and 28.4% above the Biotechnology industry median of 1.22. Kohjin Bio Co's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Kohjin Bio Co (TSE:177A), the current Debt-to-EBITDA is 1.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kohjin Bio Co Ltd is engaged in development, manufacture and sale of culture media (growing environments used for culturing microorganisms and cells) and contract manufacturing of processed cell products. It has manufacturing and sales of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics.
17GF Score
Get the complete analysis for TSE:177A
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:177A has been successfully added to your 
